Effects of Smoking on COVID-19 Management and Mortality: An Umbrella Review

SeyedAlinaghi, SeyedAhmad; Afsahi, Amir Masoud; Shahidi, Ramin; Kianzad, Shaghayegh; Pashaei, Zahra; Mirahmad, Maryam; Asili, Pooria; Mojdeganlou, Hengameh; Razi, Armin; Mojdeganlou, Paniz; Fard, Iman Amiri; Mahdiabadi, Sara; Afzalian, Arian; Dashti, Mohsen; Ghasemzadeh, Afsaneh; Parmoon, Zohal; Badri, Hajar; Mehraeen, Esmaeil; Hackett, Daniel

doi:https://doi.org/10.1155/2023/7656135

Journal of Smoking Cessation

On this page

Abstract Introduction Methods Results Conclusion Data Availability Additional Points Disclosure Conflicts of Interest Authors’ Contributions Supplementary Materials References Copyright Related Articles

Review Article | Open Access

Volume 2023 | Article ID 7656135 | https://doi.org/10.1155/2023/7656135

Effects of Smoking on COVID-19 Management and Mortality: An Umbrella Review

SeyedAhmad SeyedAlinaghi,¹Amir Masoud Afsahi,²Ramin Shahidi,³Shaghayegh Kianzad,⁴Zahra Pashaei,¹Maryam Mirahmad,⁵Pooria Asili,⁶Hengameh Mojdeganlou,⁷Armin Razi,⁸Paniz Mojdeganlou,⁹Iman Amiri Fard,¹⁰and Sara Mahdiabadi⁸ et al.

Academic Editor: Haniki Mohamed

Received28 Nov 2022

Revised22 Feb 2023

Accepted04 Apr 2023

Published13 May 2023

Abstract

Introduction. Smoking status appears to lead to a poor prognosis in COVID-19 patients. However, findings from the studies conducted on this topic have not been consistent, and further exploration is required. Methods. The objective of this umbrella review was to examine the effects of smoking on COVID-19 management and mortality. Online databases that included PubMed, Embase, Scopus, and Web of Science were searched using relevant keywords up to July 27, 2022. Articles were restricted to the English language, and the PRISMA protocol was followed. Results. A total of 27 systematic reviews, published from 2020 to 2022, were included. Individual studies included in the systematic reviews ranged from 8 to 186, with various population sizes. The consensus from the majority of systematic reviews was that COVID-19 smoker patients experience greater disease severity, disease progression, hospitalization rate, hospital admission duration, mechanical ventilation, ICU admission, and mortality rate. Conclusions. COVID-19 patients with a history of smoking (current and former) are vulnerable to adverse hospital outcomes and worse COVID-19 progression. Effective preventive and supportive approaches are required to decrease the risk of COVID-19 morbidity and mortality in patients with a history of smoking.

1. Introduction

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)—the cause of coronavirus disease 2019 (COVID-19)—first emerged in December 2019 in Wuhan, China [1–4]. The World Health Organization (WHO) declared a global COVID-19 pandemic in March 2020 [5]. As of August 8^th, 2022, COVID-19 has infected more than 581 million people and caused more than 6.4 million deaths worldwide [6]. SARS-Cov-2 is mainly an aerosol-born disease and infects new cases through respiratory droplet inhalation [7–9]. COVID-19 presents mostly with flu-like symptoms such as fever, chills, myalgia, dry cough, fatigue, back pain, headache, anorexia, diarrhea, anosmia (loss of smell sensation), and ageusia (loss of taste sensation) [10, 11]. However, 4–41% of total cases can be asymptomatic [10, 11]. Severe COVID-19 can cause acute respiratory distress syndrome (ARDS), which manifests with hypoxia, dyspnea, chest pain, altered consciousness, cyanosis, and eventual death. It mainly occurs among older adults (i.e., >65 years) and vulnerable populations including patients with chronic kidney, liver, or lung disease, diabetes mellitus, obesity, HIV infection, and smoking history [12].

Smokers are more predisposed to viral and bacterial pulmonary infections including influenza, tuberculosis, and bacterial pneumonia [13–16]. In the first months of the pandemic in 2020, it was reported that Chinese patients with severe COVID-19 were mostly COPD patients or current smokers [17]. In addition, one of the earliest systematic reviews concluded that smoking is negatively associated with COVID-19 progression and prognosis [18]. Some studies have reported higher expression of angiotensin-converting enzyme 2 (ACE-2), which is the main receptor of SARS-CoV-2, in the lower respiratory airways of current smokers and COPD patients compared to nonsmokers, and stated that smoking and COPD could contribute to a higher COVID-19 incidence and relatively poorer outcomes [19, 20]. Conversely, some studies have reported lower levels of ACE-2 among smokers compared to nonsmokers [21, 22], and one preliminary meta-analysis of five studies in China stated smoking may not be significantly associated with an increased risk of severe disease among COVID-19 patients [23].

There have been five other meta-analyses conducted where the findings support the hypothesis that COPD and current smoking status contribute to worse progression and poor outcomes among COVID-19 patients [24–28]. One of the meta-analyses specifically stated that smoking can have negative adverse impacts on disease severity and mortality among hospitalized COVID-19 patients, with more impact on nondiabetic younger patients [27]. In addition, another meta-analysis specified that both current smoking and previous history of smoking increase COVID-19 severity significantly, while previous history of smoking increases the mortality risk [28]. Now that almost three years has passed since the first report of SARS-CoV-2 in human population, and large sample-sized studies and more reliable data are available, further investigation of COVID-19 and smoking is warranted. The aim of this review was to examine the associations between COVID-19 and smoking status (current smoker or history of smoking), answer the controversial paradoxes, and fill the gaps in the literature.

2. Methods

The objective of this umbrella study was to explore the prevailing systematic review literature pertaining the associations between COVID-19 and smoking status (being a current smoker or having history of smoking) and effects of smoking on COVID-19 management and mortality. In order to substantiate the results, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was followed. Quality of studies was evaluated with the NIH quality assessment tool.

2.1. Data Sources

An extensive search of four online databases was performed which included PubMed, Scopus, Embase, and Web of Science as data sources. Articles were restricted to the English language, and the search was conducted up to July 27, 2022. The following keywords and their combinations were used during the search: (a)“COVID-19” OR “Novel coronavirus” OR “2019-nCoV” OR “SARS-CoV-2” OR “SARS- CoV2” [Title/Abstract](b)“Smoking” [Title/Abstract](c)“Systematic review” [Title/Abstract](d)[A] AND [B] AND [C]

2.2. Study Selection

In order to improve the study selection process, a two-step method was employed. The first step consisted of screening literature with regard to titles and abstracts. This was done by five researchers. The second step was performed by another five researchers, involving screening of full texts that were potentially eligible. Articles that met the inclusion criteria were advanced to the next step of data extraction. Articles were included if they had a systematic review nature and were peer-reviewed report on smoking and COVID-19. The exclusion criteria included studies lacking published data investigations, nonhuman research studies, duplications, abstracts with deficient full texts, editorial letters, conference abstracts, case series, and case reports.

2.3. Data Extraction

Data of publications having met the eligibility criteria and passing the second step of selection process was meticulously extracted and gathered in Table 1. Five researchers investigated the full texts and extracted these study requisites. Any duplicates were removed, and the accuracy of the extracted data was checked.

2.4. Quality and Risk of Bias Assessment

Study quality and risk of bias was assessed with the National Institute of Health (NIH) Quality Assessment (QA) Tools for Case Series Studies. Two independent reviewers rated the quality of the included studies. Table 2 shows the results of the study quality and risk of bias. The scoring strategy of this tool has been explained at the bottom of this table.

3. Results

The database search yielded 113 potential studies (after duplicates removed), and following the screening, a total of 27 articles met the eligibility criteria (Figure 1). The included systematic reviews were published between 2020 and 2022. One study included was designed as reviews of reviews [33].

Included studies were from China, the USA, Spain, Greece, Thailand, Canada, Indonesia, Japan, and other countries. China (7 studies) and the USA (5 studies) were the countries most represented. The 27 systematic reviews included a wide range of studies (i.e., 8 to 186 studies) with different populations (from 17 to 1,304,587 patients among mentioned populations). Males were the dominant population in 6 studies [29, 32, 37, 48, 49]. Table 1 shows the characteristics of the studies.

Smoking history was categorized as smokers and nonsmokers in some studies [46, 49], while most studies evaluated the smoking status as current and former smokers with comparisons between these groups [18, 40–42, 47]. One study represented smokers based on smoking heaviness, lifetime smoking, and smoking initiation [39].

Most of the studies concluded that smoker’s with COVID-19 had a worse outcome and higher mortality rate [27, 30, 34, 36]. Evaluating the hospital admission rate, most of the studies showed increased risk of hospital admissions in smokers [18, 29, 30], while one study showed that smokers had lower risk of hospital admission [33].

The majority of studies found that smoking was associated with increased risk for mechanical ventilation [18, 29, 30]; however, there was one study showing no association between smoking status and risk of mechanical ventilation [51]. These results are shown in Table 3.

4. Discussions

According to the NIH’s LitCovid database, more than 291,000 articles related to COVID-19 have been published to date, which shows the explosion of research in this field. This incredible amount of research has increased the information on different aspects of the disease. However, knowledge is still lacking in some areas with further research required to better understand COVID-19 and its effects. This umbrella review is aimed at organizing and updating the existing body of literature on the effects of smoking on COVID-19.

The overall findings support the hypothesis of increased severity of disease in COVID-19 smoker patients. Specifically, smoking is linked to more advanced COVID-19 outcomes, as manifested by the necessity for ICU admission, mechanical ventilation, and COVID-19-related death. Nevertheless, only a few studies demonstrated no significant link between smoking and COVID-19-related mortality [30] and mechanical ventilation [51]. Additionally, only one study found no link between smoking and an increased risk of death from COVID-19 [27]. Notably, a study in England, that investigated approximately 17 million patient documents, discovered that increased COVID-19-related mortality linked to smoking no longer remained significant after adjustment for the presence of preexisting chronic pulmonary disease. This suggests that smoking-induced comorbidities may be the cause of the overall death toll among COVID-19 smoker patients [53]. The results emphasize the need for further research elucidating the mechanisms by which smoking increases the incidence of unfavorable outcomes in COVID-19 patients.

Various potentially harmful compounds are present in tobacco products. Moreover, further chemicals are formed during aerosolization as a result of combustion or heating. Previous studies have demonstrated that pulmonary epithelium and vascular endothelium are both damaged by harmful compounds in cigarette smoke. The mucociliary clearance and epithelial barrier are compromised by damage to epithelial cells. Additionally, injured cells release modified molecules that activate specific lung receptors, activating acquired and innate immune responses [54]. Through a variety of mechanisms including the direct effect of nicotine, reperfusion injury after carbon monoxide-induced hypoxia, and particulate matter’s abundance, tobacco smoke ingredients cause oxidative stress [55, 56].

The angiotensin II conversion enzyme-2 (ACE2) receptor, which is abundant in mucosal respiratory epithelial cells, has been associated with COVID-19 infection. It is probably the most reasonable explanation for the potential increased risk of death among smokers. Infection by the host-virus binding to the ACE2 receptors is likely a critical stage in SARS-CoV-2 infection [57–59]. Smokers have significantly higher levels of pulmonary ACE2 gene expression compared to nonsmokers [60]. Tobacco use can cause oxidative stress and inflammation in the lungs, making smokers more susceptible to bacterial or viral diseases [58, 61]. Oxidative stress reduces epithelial permeability, which may have substantial consequences for smokers with COVID-19 disease [62, 63]. Likewise, smoking leads to cardiovascular disease, chronic lung illness, diabetes, and other comorbidities that are related to worse outcomes in patients with COVID-19 infection [64].

On the contrary, there is evidence demonstrating that smoking may exert positive effects on COVID-19 disease severity, mediated by nicotine [51]. It is important to keep in mind that specific cigarette ingredients, like nicotine, may affect ACE2 differently from entire cigarettes [65]. The underlying mechanism might be attributed to the evidence showing nicotine might decrease tumor necrosis factor (TNF) expression in airway epithelial cells [66]. Moreover, nicotine may act as an agonist of the cholinergic anti-inflammatory pathway, which regulates the immune response and inflammatory reaction [67, 68].

Factors responsible for higher susceptibility of smokers to COVID-19 are briefly discussed here to better understand the mechanisms about how smoking can affect the human body: (i)Smoking causes significant pathological changes including the mucosal epithelial barrier and an increase in the permeability of epithelial cells, which makes smokers more prone to be defeated against the virus invasion [69](ii)Angiotensin-converting enzyme 2 (ACE 2) is defined as the principal receptor for SARS-CoV-2 virus to enter the host cell. ACE 2 expression is upregulated in the small airway epithelium of smokers, so the virus tends to invade host cells more easily. This upregulated receptor expression is one of the negative influences of oxidative stress due to smoking [20](iii)Smoking can reduce the function of the immune system by causing a reduction in the number of CD4 + T cell (also named T helper cell, which activates macrophage or B cell), inhibiting the production of interleukin-22 (which moderates lung inflammation) and also, by promoting the secretion of catecholamines (which will weaken the immune system) [70, 71](iv)The most serious complication of COVID-19 disease is acute respiratory distress syndrome (ARDS), as a result of the cytokine storm. In this situation, large amounts of proinflammatory cytokines and chemokines such as IP-10, IL-6, TNF-α, IFN-γ, IL-2, IL-7, and GM-CSF are released and entail severe immune system response which eventually causes lung inflammation and damage. In former smokers, the expression of IL-6, TNF-α, and other proinflammatory factors are increased [72]

Although most of the reviewed articles support the hypothesis that nicotine, the main component of cigarettes, increases the odds of developing severe illness of COVID-19, it is unknown whether the harm is related to nicotine or other toxic ingredients in cigarettes. Even some articles indicate that nicotine may have anti-inflammatory effects. Nicotine has been found to prevent acute lung damage and restrain the expression of tumor necrosis factor (TNF), which plays role in the inflammatory response [66]. Furthermore, nicotine is an agonist of the cholinergic anti-inflammatory pathway that modulates immune and inflammatory reaction [51, 73].

There have been a few original research studies comparing former and current smokers. The lung may heal when someone quits smoking, which may bias the findings if former smokers are part of the exposed group since one study found that the death rate among former smokers reduces with age [44, 45]. As a result, the frequency of smokers may have been underestimated, and some former smokers may have been incorrectly classified as nonsmokers [51]. As a result, only a few systematic reviews compared the features of these two groups. Three studies found that current smokers had lower risks of an adverse outcome than former smokers [31, 35, 51]. This might be because former smokers are more likely to be older, smoked for a longer period than current smokers, or because they have concomitant conditions such as asthma or COPD as a result of smoking [51]. Another factor might be that current smokers reported their status less than former smokers. [50], although a study found that current smokers had a greater likelihood of adverse outcomes than former smokers and nonsmokers [47].

Overall, compared with nonsmokers, smokers have higher risks of severe forms of the disease and hospitalization, and mortality [18, 39, 74]. On the contrary, the severity of COVID-19 was not associated with current or former smoking but with the comorbidities caused by smoking [75, 76]. In this study, the incidence of infection by SARS CoV-2 virus in smokers and nonsmokers cannot be evaluated clearly due to the lack of data at this present time.

5. Conclusion

There is strong evidence that smoking increases the risks of disease severity/progression, hospitalization, and mortality among COVID-19 patients. Encouraging smokers to quit using, early initiation of treatment after the onset of symptoms, timely vaccination, and promoting other preventive behaviors by public health providers can control the possibility of these people getting the infection and a better prognosis. Vaccination of smokers should be done completely among the priority groups.

Data Availability

The authors stated that all information provided in this article could be shared.

Additional Points

Implications. (i) There is strong evidence that smoking increases the risks of disease severity/progression, hospitalization, and mortality among COVID-19 patients. (ii) Encouraging smokers to quit using, early initiation of treatment after the onset of symptoms, timely vaccination, and promoting other preventive behaviors by public health providers can control the possibility of these people getting the infection and a better prognosis. (iii) Vaccination of smokers should be done completely among the priority groups.

Disclosure

The present study was conducted in collaboration with the Khalkhal University of Medical Sciences, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, and the University of Sydney.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this manuscript.

Authors’ Contributions

Esmaeil Mehraeen and SeyedAhmad SeyedAlinaghi are responsible for the conception and design of the study; Amir Masoud Afsahi and Ramin Shahidi for the acquisition of data; Esmaeil Mehraeen, Shaghayegh Kianzad, Zahra Pashaei, Maryam Mirahmad, Pooria Asili, Hengameh Mojdeganlou, Armin Razi, Paniz Mojdeganlou, Iman Amiri Fard, Sara Mahdiabadi, Arian Afzalian, Mohsen Dashti, Afsaneh Ghasemzadeh, Zohal Parmoon, and Hajar Badri for the drafting of the article; SeyedAhmad SeyedAlinaghi, Daniel Hackett, and Amir Masoud Afsahi for revising it critically for important intellectual content; and SeyedAhmad SeyedAlinaghi, Esmaeil Mehraeen, and Daniel Hackett for the final approval of the version to be submitted.

Supplementary Materials

Supplementary table 1: description of the findings reported in the eligible studies. (Supplementary Materials)

References

D. Davies, A. McDougall, and W. Yoong, “COVID-19 vaccination during pregnancy: coverage and safety, a comment,” American Journal of Obstetrics and Gynecology, vol. 227, no. 2, p. 370, 2022.
View at: Publisher Site | Google Scholar
E. Mehraeen, O. Dadras, A. M. Afsahi et al., “Vaccines for COVID-19: a systematic review of feasibility and effectiveness,” Infectious Disorders Drug Targets, vol. 22, no. 2, article e230921196758, 2022.
View at: Publisher Site | Google Scholar
S. SeyedAlinaghi, A. Karimi, H. Mojdeganlou et al., “Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: a systematic review,” SAGE Open Medicine, vol. 10, 2022.
View at: Google Scholar
S. Oliaei, S. SeyedAlinaghi, M. Mehrtak et al., “The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review,” European Journal of Medical Research, vol. 26, no. 1, p. 96, 2021.
View at: Publisher Site | Google Scholar
E. Mehraeen, M. A. Salehi, F. Behnezhad, H. R. Moghaddam, and A. S. Seyed, “Transmission modes of COVID-19: a systematic review,” Infectious Disorders Drug Targets, vol. 21, no. 6, article e170721187995, 2021.
View at: Publisher Site | Google Scholar
World Health Organization, “WHO coronavirus (COVID-19) dashboard,” 2022, https://covid19.who.int/.
View at: Google Scholar
Centers for Disease Control and Prevention, “Transmission,” 2021, https://www.cdc.gov/coronavirus/2019-ncov/transmission/index.html.
View at: Google Scholar
E. Mehraeen, Z. Najafi, B. Hayati et al., “Current treatments and therapeutic options for COVID-19 patients: a systematic review,” Infectious Disorders Drug Targets, vol. 22, no. 1, article e260721194968, 2022.
View at: Publisher Site | Google Scholar
S. Seyed Alinaghi, A. Karimi, and A. Barzegary, “Mucormycosis infection in patients with COVID-19: a systematic review,” Health Science Reports, vol. 5, no. 2, article e529, 2022.
View at: Publisher Site | Google Scholar
Centers for Disease Control and Prevention, “Symptoms of COVID-19,” 2022, https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.
View at: Google Scholar
O. Byambasuren, M. Cardona, K. Bell, J. Clark, M.-L. McLaws, and P. Glasziou, “Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis,” Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, vol. 5, no. 4, pp. 223–234, 2020.
View at: Publisher Site | Google Scholar
G. P. Ramadori, “SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death,” Medical Sciences, vol. 10, no. 4, p. 58, 2022.
View at: Publisher Site | Google Scholar
B. Atto, M. S. Eapen, P. Sharma et al., “New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways,” Clinical Science, vol. 133, no. 14, pp. 1663–1703, 2019.
View at: Publisher Site | Google Scholar
M. S. Eapen, P. Sharma, Y. P. Moodley, P. M. Hansbro, and S. S. Sohal, “Dysfunctional immunity and microbial adhesion molecules in smoking-induced pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 199, no. 2, pp. 250-251, 2019.
View at: Publisher Site | Google Scholar
M. S. Eapen, P. Sharma, and S. S. Sohal, “Mitochondrial dysfunction in macrophages: a key to defective bacterial phagocytosis in COPD,” European Respiratory Journal, vol. 54, no. 4, article 1901641, 2019.
View at: Publisher Site | Google Scholar
R. M. Tuder and J. H. Yun, “It takes two to tango: cigarette smoke partners with viruses to promote emphysema,” The Journal of Clinical Investigation, vol. 118, no. 8, pp. 2689–2693, 2008.
View at: Publisher Site | Google Scholar
W. J. Guan, Z. Y. Ni, Y. Hu et al., “Clinical characteristics of coronavirus disease 2019 in China,” New England Journal of Medicine, vol. 382, no. 18, pp. 1708–1720, 2020.
View at: Google Scholar
C. I. Vardavas and K. Nikitara, “COVID-19 and smoking: a systematic review of the evidence,” Tobacco Induced Diseases, vol. 18, p. 20, 2020.
View at: Google Scholar
M. Jacobs, H. P. Van Eeckhoutte, S. R. Wijnant et al., “Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects,” The European Respiratory Journal, vol. 56, no. 2, 2020.
View at: Google Scholar
J. M. Leung, C. X. Yang, A. Tam et al., “ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19,” The European Respiratory Journal, vol. 55, no. 5, 2020.
View at: Google Scholar
J. M. Oakes, R. M. Fuchs, J. D. Gardner, E. Lazartigues, and X. Yue, “Nicotine and the renin-angiotensin system,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 315, no. 5, pp. R895–R906, 2018.
View at: Google Scholar
Y. Wan, J. Shang, R. Graham, R. S. Baric, and F. Li, “Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus,” Journal of Virology, vol. 94, no. 7, 2020.
View at: Google Scholar
G. Lippi and B. M. Henry, “Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19),” European Journal of Internal Medicine, vol. 75, pp. 107-108, 2020.
View at: Google Scholar
Q. Zhao, M. Meng, R. Kumar et al., “The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis,” Journal of Medical Virology, vol. 92, no. 10, pp. 1915–1921, 2020.
View at: Google Scholar
Z. Zheng, F. Peng, B. Xu et al., “Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis,” Journal of Infection, vol. 81, no. 2, pp. e16–e25, 2020.
View at: Publisher Site | Google Scholar
P. A. S. Astuti, “COVID-19 pandemic: an opportunity to enhance tobacco control in Indonesia,” Nicotine & Tobacco Research, vol. 22, no. 9, pp. 1653–1656, 2020.
View at: Google Scholar
A. Karanasos, K. Aznaouridis, G. Latsios et al., “Impact of smoking status on disease severity and mortality of hospitalized patients with COVID-19 infection: a systematic review and meta-analysis,” Nicotine & Tobacco Research, vol. 22, no. 9, pp. 1657–1659, 2020.
View at: Publisher Site | Google Scholar
R. K. Reddy, W. N. Charles, A. Sklavounos, A. Dutt, P. T. Seed, and A. Khajuria, “The effect of smoking on COVID-19 severity: a systematic review and meta-analysis,” Journal of Medical Virology, vol. 93, no. 2, pp. 1045–1056, 2021.
View at: Google Scholar
S. A. Alghamdi, A. S. Alahmari, S. K. Bajari et al., “Smoking and severity of COVID-19 infection: a short systematic review and meta-analysis,” Annals of Medical and Health Sciences Research, vol. 10, no. 5, pp. 1083–1088, 2020.
View at: Google Scholar
J. Baker, N. Krishnan, L. C. Abroms, and C. J. Berg, “The impact of tobacco use on COVID-19 outcomes: a systematic review,” Journal of Smoking Cessation, vol. 2022, article 5474397, 11 pages, 2022.
View at: Publisher Site | Google Scholar
K. Farsalinos, A. Barbouni, K. Poulas, R. Polosa, P. Caponnetto, and R. Niaura, “Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis,” Therapeutic Advances in Chronic Disease., vol. 11, 2020.
View at: Google Scholar
J. González-Rubio, C. Navarro-López, E. López-Nájera et al., “A systematic review and meta-analysis of hospitalised current smokers and COVID-19,” International Journal of Environmental Research and Public Health, vol. 17, no. 20, 2020.
View at: Publisher Site | Google Scholar
E. J. Grundy, T. Suddek, F. T. Filippidis, A. Majeed, and S. Coronini-Cronberg, “Smoking, SARS-CoV-2 and COVID-19: a review of reviews considering implications for public health policy and practice,” Tobacco Induced Diseases, vol. 18, 2020.
View at: Google Scholar
A. Gülsen, B. A. Yigitbas, B. Uslu, D. Drömann, and O. Kilinc, “The effect of smoking on COVID-19 symptom severity: systematic review and meta-analysis,” Pulmonary Medicine, vol. 2020, Article ID 7590207, 11 pages, 2020.
View at: Publisher Site | Google Scholar
H. Hou, Y. Li, P. Zhang et al., “Smoking is independently associated with an increased risk for COVID-19 mortality: a systematic review and meta-analysis based on adjusted effect estimates,” Nicotine & Tobacco Research, vol. 23, no. 11, pp. 1947–1951, 2021.
View at: Publisher Site | Google Scholar
S. Kang, X. Gong, and Y. Yuan, “Association of smoking and cardiovascular disease with disease progression in COVID-19: a systematic review and meta-analysis,” Epidemiology and Infection, vol. 149, pp. 1–26, 2021.
View at: Publisher Site | Google Scholar
R. Kumar, A. K. Rai, M. M. Phukan et al., “Accumulating impact of smoking and co-morbidities on severity and mortality of COVID-19 infection: a systematic review and meta-analysis,” Current Genomics, vol. 22, no. 5, pp. 339–352, 2021.
View at: Publisher Site | Google Scholar
J. Li, X. He, Y. Yuan et al., “Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia,” American Journal of Infection Control, vol. 49, no. 1, pp. 82–89, 2021.
View at: Publisher Site | Google Scholar
S. Luo, Y. Liang, T. H. T. Wong, C. M. Schooling, and S. L. Au Yeung, “Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies,” International Journal of Epidemiology, vol. 51, no. 4, pp. 1088–1105, 2022.
View at: Publisher Site | Google Scholar
Y. Mahamat-Saleh, T. Fiolet, M. E. Rebeaud et al., “Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies,” BMJ Open, vol. 11, no. 10, article e052777, 2021.
View at: Publisher Site | Google Scholar
P. P. Mattey-Mora, C. A. Begle, C. K. Owusu, C. Chen, and M. A. Parker, “Hospitalised versus outpatient COVID-19 patients' background characteristics and comorbidities: a systematic review and meta-analysis,” Reviews in Medical Virology, vol. 32, no. 3, p. e2306, 2022.
View at: Publisher Site | Google Scholar
A. E. Mesas, I. Cavero-Redondo, C. Álvarez-Bueno et al., “Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions,” PloS One, vol. 15, no. 11, article e0241742, 2020.
View at: Publisher Site | Google Scholar
L. H. N. Minh, A. A. F. Abozaid, N. X. Ha et al., “Clinical and laboratory factors associated with coronavirus disease 2019 (Covid-19): a systematic review and meta-analysis,” Reviews in Medical Virology, vol. 31, no. 6, article e2288, 2021.
View at: Publisher Site | Google Scholar
R. Patanavanich and S. A. Glantz, “Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis,” BMC Public Health, vol. 21, no. 1, p. 1554, 2021.
View at: Google Scholar
R. Patanavanich, T. Siripoon, S. Amponnavarat, and S. A. Glantz, “Active smokers are at higher risk of COVID-19 death: a systematic review and meta-analysis,” Nicotine & Tobacco Research, vol. 25, no. 2, pp. 177–184, 2023.
View at: Publisher Site | Google Scholar
T. M. Plasencia-Urizarri, R. Aguilera-Rodríguez, and L. E. Almaguer-Mederos, “Comorbidities and clinical severity of COVID-19: systematic review and meta-analysis,” Revista Habanera de Ciencias Medicas, vol. 19, 2020.
View at: Google Scholar
R. Pranata, A. Y. Soeroto, I. Huang et al., “Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19,” The International Journal of Tuberculosis and Lung Disease, vol. 24, no. 8, pp. 838–843, 2020.
View at: Publisher Site | Google Scholar
D. C. Sanchez-Ramirez and D. Mackey, “Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: a systematic review and meta-analysis,” Respiratory Medicine, vol. 171, article 106096, 2020.
View at: Publisher Site | Google Scholar
E. H. Taylor, E. J. Marson, M. Elhadi et al., “Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis,” Anaesthesia, vol. 76, no. 9, pp. 1224–1232, 2021.
View at: Publisher Site | Google Scholar
A. Umnuaypornlert, S. Kanchanasurakit, D. E. Lucero-Prisno, and S. Saokaew, “Smoking and risk of negative outcomes among COVID-19 patients: a systematic review and meta-analysis,” Tobacco Induced Diseases, vol. 19, 2021.
View at: Google Scholar
H. M. Zhang, S. D. Ma, T. T. Han et al., “Association of smoking history with severe and critical outcomes in COVID-19 patients: a systemic review and meta-analysis,” European Journal of Integrative Medicine, vol. 43, article 101313, 2021.
View at: Publisher Site | Google Scholar
T. Zhang, W. S. Huang, W. Guan et al., “Risk factors and predictors associated with the severity of COVID-19 in China: a systematic review, meta-analysis, and meta-regression,” Journal of Thoracic Disease, vol. 12, no. 12, pp. 7429–7441, 2020.
View at: Publisher Site | Google Scholar
E. J. Williamson, A. J. Walker, K. Bhaskaran et al., “Factors associated with COVID-19-related death using OpenSAFELY,” Nature, vol. 584, no. 7821, pp. 430–436, 2020.
View at: Publisher Site | Google Scholar
T. Nyunoya, Y. Mebratu, A. Contreras, M. Delgado, H. S. Chand, and Y. Tesfaigzi, “Molecular processes that drive cigarette smoke-induced epithelial cell fate of the lung,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 3, pp. 471–482, 2014.
View at: Google Scholar
H. Qasim, A. B. Alarabi, K. H. Alzoubi, Z. A. Karim, F. Z. Alshbool, and F. T. Khasawneh, “The effects of hookah/waterpipe smoking on general health and the cardiovascular system,” Environmental Health and Preventive Medicine, vol. 24, no. 1, p. 58, 2019.
View at: Google Scholar
C. A. Piantadosi, “Carbon monoxide, reactive oxygen signaling, and oxidative stress,” Free Radical Biology & Medicine, vol. 45, no. 5, pp. 562–569, 2008.
View at: Google Scholar
L. Arcavi and N. L. Benowitz, “Cigarette smoking and infection,” Archives of Internal Medicine, vol. 164, no. 20, pp. 2206–2216, 2004.
View at: Google Scholar
C. M. T. Bauer, M. C. Morissette, and M. R. Stämpfli, “The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically,” Chest, vol. 143, no. 1, pp. 196–206, 2013.
View at: Google Scholar
A. Strzelak, A. Ratajczak, A. Adamiec, and W. Feleszko, “Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review,” International Journal of Environmental Research and Public Health, vol. 15, no. 5, p. 1033, 2018.
View at: Google Scholar
G. Cai, Y. Bossé, F. Xiao, F. Kheradmand, and C. I. Amos, “Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2,” American Journal of Respiratory and Critical Care Medicine, vol. 201, no. 12, pp. 1557–1559, 2020.
View at: Publisher Site | Google Scholar
H. Yao and I. Rahman, “Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease,” Toxicology and Applied Pharmacology, vol. 254, no. 2, pp. 72–85, 2011.
View at: Publisher Site | Google Scholar
R. S. Wiener, Y. X. Cao, A. Hinds, M. I. Ramirez, and M. C. Williams, “Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung,” Journal of Cellular Biochemistry, vol. 101, no. 5, pp. 1278–1291, 2007.
View at: Google Scholar
Y. Meng, T. Li, G. S. Zhou et al., “The angiotensin-converting enzyme 2/angiotensin (1–7)/mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/rho kinase pathway,” Antioxidants & Redox Signaling, vol. 22, no. 3, pp. 241–258, 2015.
View at: Google Scholar
S. Richardson, J. S. Hirsch, M. Narasimhan et al., “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area,” Journal of the American Medical Association, vol. 323, no. 20, pp. 2052–2059, 2020.
View at: Publisher Site | Google Scholar
M. F. Ferrari, M. K. Raizada, and D. R. Fior-Chadi, “Differential regulation of the renin-angiotensin system by nicotine in WKY and SHR glia,” Journal of Molecular Neuroscience, vol. 35, no. 2, pp. 151–160, 2008.
View at: Google Scholar
Q. Li, X. D. Zhou, V. P. Kolosov, and J. M. Perelman, “Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells,” Cellular Physiology and Biochemistry, vol. 27, no. 5, pp. 605–612, 2011.
View at: Publisher Site | Google Scholar
H. Wang, M. Yu, M. Ochani et al., “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation,” Nature, vol. 421, no. 6921, pp. 384–388, 2003.
View at: Publisher Site | Google Scholar
K. J. Tracey, “Physiology and immunology of the cholinergic antiinflammatory pathway,” The Journal of Clinical Investigation, vol. 117, no. 2, pp. 289–296, 2007.
View at: Google Scholar
M. Aghapour, P. Raee, S. J. Moghaddam, P. S. Hiemstra, and I. H. Heijink, “Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: role of cigarette smoke exposure,” American Journal of Respiratory Cell and Molecular Biology, vol. 58, 2018.
View at: Google Scholar
H. M. H. Nguyen, J. A. Torres, S. Agrawal, and A. Agrawal, “Nicotine impairs the response of lung epithelial cells to IL-22,” Mediators of inflammation, vol. 2020, Article ID 6705428, 9 pages, 2020.
View at: Publisher Site | Google Scholar
H. E. Yue, S. U. Jian, D. I. Xiaoqian, and W. A. Qiang, “Mechanisms in which smoking increases the risk of covid-19 infection: a narrative review,” Iranian Journal of Public Health, vol. 50, 2021.
View at: Publisher Site | Google Scholar
X. Li, M. Geng, Y. Peng, L. Meng, and S. Lu, “Molecular immune pathogenesis and diagnosis of COVID-19,” Journal of Pharmaceutical Analysis, vol. 10, 2020.
View at: Google Scholar
K. J. Tracey, “Physiology and immunology of the cholinergic antiinfammatory pathway,” The Journal of clinical investigation, vol. 117, 2007.
View at: Google Scholar
A. K. Clift, A. Von Ende, P. San Tan et al., “Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort,” Thorax, vol. 77, 2022.
View at: Google Scholar
Y. Matsushita, T. Yokoyama, K. Hayakawa et al., “Smoking and severe illness in hospitalized COVID-19 patients in Japan,” International Journal of Epidemiology, vol. 51, no. 4, pp. 1078–1087, 2022.
View at: Publisher Site | Google Scholar
A. Korzeniowska, G. Ręka, M. Bilska, and H. Piecewicz-Szczęsna, “The smoker’s paradox during the COVID-19 pandemic? The influence of smoking and vaping on the incidence and course of SARS-CoV-2 virus infection as well as possibility of using nicotine in the treatment of COVID-19 - review of the literature,” Przegląd Epidemiologiczny, vol. 75, 2021.
View at: Google Scholar

Copyright

Copyright © 2023 SeyedAhmad SeyedAlinaghi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

419

Downloads

251

Citations